Clinical Trial Results:
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed with Wild-Type Transthyretin Cardiac Amyloidosis.
Summary
|
|
EudraCT number |
2020-001617-21 |
Trial protocol |
DK |
Global end of trial date |
07 Aug 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Oct 2024
|
First version publication date |
29 Oct 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
72864
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Aarhus University Hospital
|
||
Sponsor organisation address |
Palle Juul-Jensens Boulevard 99, Aarhus, Denmark,
|
||
Public contact |
Department of Cardiology, Aarhus University Hospital, berlad@rm.dk
|
||
Scientific contact |
Department of Cardiology, Aarhus University Hospital, berlad@rm.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Jul 2024
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
07 Aug 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study is:
1) to characterize the oxidative capacity of myocardial mitochondria as well as to investigate the treatment effect of Trimetazidine (TMZ) in patients with stage 1 cardiac amyloidosis in a double-blind, placebo-controlled cross-over study;
2) to examine the effect of TMZ at rest and during exercise on systolic and diastolic function measured by right heart catheterization (RHC) and advanced echocardiography;
3) to investigate and characterize the morphology of myocardial myocytes and mitochondria by electron microscopy;
4) to compare the oxidative capacity, morphology, and myocardial function of mitochondria in patients with early-stage asymptomatic disease versus patients with more advanced symptomatic disease.
|
||
Protection of trial subjects |
Data monitoring was performed by the Good Clinical Practice Unit at Aarhus University.
All subject were enrolled after providing written informed consent.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Sep 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 24
|
||
Worldwide total number of subjects |
24
|
||
EEA total number of subjects |
24
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
22
|
||
85 years and over |
2
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Patients with early-stage wild-type transthyretin cardiac amyloidosis were recruited at the department of cardiology at Aarhus University Hospital. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Inclusion criteria - Age ≥ 60 years for men. Age ≥ 70 years for women - TC99-DPD-scintigraphy positive for cardiac involvement - Negative serum immunofixation - Normal Kappa/Lambda ratio - NAC stage I (NT-proBNP ≤ 3000 ng/L, eGFR ≥ 45 mL/min) - NYHA-class I-IIa - Written informed consent | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Baseline
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
No
|
|||||||||||||||
Arm title
|
Trimetazidine | |||||||||||||||
Arm description |
Trimetazidine 20 mg three times daily | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
trimetazidine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Capsule, hard + tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
20 mg three times daily
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Placebo three times daily | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Capsule, hard + tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Placebo three times daily
|
|||||||||||||||
|
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
Treatment
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Data analyst | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Trimetazidine | |||||||||||||||
Arm description |
Trimetazidine 20 mg times three daily | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
trimetazidine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Capsule, hard + tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
20 mg three times daily
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Placebo capsule three times daily | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Capsule, hard + tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Placebo three times daily
|
|||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Trimetazidine
|
||
Reporting group description |
Trimetazidine 20 mg three times daily | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo three times daily | ||
Reporting group title |
Trimetazidine
|
||
Reporting group description |
Trimetazidine 20 mg times three daily | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo capsule three times daily |
|
|||||||||||||
End point title |
Pulmonary artery wedge pressure at peak exercise | ||||||||||||
End point description |
The primary end point was a difference in peak pulmonary artery wedge pressure at peak exercise between trimetazidine and placebo.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
..
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Linear mixed model | ||||||||||||
Comparison groups |
Trimetazidine v Placebo
|
||||||||||||
Number of subjects included in analysis |
44
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Cardiac mitochondrial oxidative capacity | ||||||||||||
End point description |
The secondary end point was cardiac mitochondrial oxidative phosphorylation capacity.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Linear mixed model | ||||||||||||
Comparison groups |
Trimetazidine v Placebo
|
||||||||||||
Number of subjects included in analysis |
44
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
01Nov2020 to 01Aug2023
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Collected by the study team and assessed by the investigator and supervisor.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |